于 明加

于明加，博士毕业于北京理工大学。主要从事创新药物研究，长期致力于小分子和生物大分子化合物药物构效关系的研究。利用计算机辅助药物设计方法，开展基于药物与受体三维结构的药物设计研究，发现了多种有望发展成新药的化合物。这些创新的研究工作促进了有机化学、生命科学和计算机科学的跨学科研究。

(1) 医用多糖先导化合物的设计与开发；
(2) 功能性小分子多肽先导药物的开发；
(3) 致病菌、冠状病毒感染类疾病治疗靶点挖掘；
(4) 新型抗菌类靶向药物的设计与开发。

2015.9-2019.6 北京理工大学化学与化工学院，化学专业，理学博士
2012.9-2015.6 哈尔滨医科大学和武汉大学联合培养，药学专业，理学硕士
2007.9-2012.6 哈尔滨医科大学，临床药学专业，理学学士

2021.9-至今 北京理工大学化学与化工学院，特别副研究员，硕士生导师
2019.6-2021.8 北京化工大学软物质科学与工程高精尖创新中心与乌普萨拉大学联合培养博士后

主持项目情况：
1.2019.12-2022.11，作为项目骨干参与科技部可再生能源与氢能重点研发计划，2019YFB150059，生物质连续化制备高品质生物柴油关键技术
2.2020.9-2021.6，主持中国博士后“第67批面上资助基金”，2020M670109，理性设计硫酸乙酰肝素类药物用于新型冠状病毒感染的疾病治疗
3.2020.10-2022.6，主持中国博士后“第2批特别资助”，2020TQ0029，基于冠状病毒刺突蛋白受体结合域理性设计硫酸乙酰肝素类抗病毒药物
4.2021.12-2025.5，参与科技部国家质量基础设施体系重点研发计划，SQ2021YFF0600005，新兴生物功能性物质结构关键计量技术研究
5.2021.9-2024.9，主持北京理工大学青年教师学术启动计划，3100012222222，硫酸乙酰肝素类抗冠状病毒先导化合物的发现及其分子机理研究
6.2023.1-2025.12，主持国家自然科学基金青年科学基金，32201053，硫酸乙酰肝素类抗冠状病毒先导化合物的发现及其分子机理研究
7.2022.10-2024.10，主持军委科技委专项工程项目，***的生物法制造技术
8.2023.1-2025.12，参与国家自然科学基金面上基金，52271254，复合型金属微机电系统的构建及其在肿瘤类器官生长实时监测和原位基因表达调控中的应用研究
9.2023.1-2023.12，参与北京理工大学科技创新计划-科研基地科技支撑专项计划，3100012212314，硫酸乙酰肝素类抗冠状病毒先导化合物的发现
10.2023.11-2026.12，参与北京市自然科学基金-海淀原始创新联合基金重点研究专题项目，L232017，基于孟德尔随机化分析的多发性硬化潜在治疗药物筛选及评价
11.2024.1-2024.12，参与四川省重点研发项目，24SYSX0230，AI驱动的双作用模式新型抗菌药物研发
发表文章情况：
[1]Zi-Qiang Feng, Jing Ding, Min-Zhen Zhu, Wei-Song Xie, Rui-Chen Liu, Si-Si Liu, Si-Meng Liu, Ming-Jia Yu*, Xin-Hong Zhu*, Jian-Hua Liang*. Discovery of a novel lead characterized by a stilbene-extended scaffold against sepsis as soluble epoxide hydrolase inhibitors. Eur. J. Med. Chem., 2024, https://doi.org/10.1016/j.ejmech.2023.116113.
[2]Kiran Shehzadi, Afsheen Saba, Mingjia Yu*, Jianhua Liang*. Structure-Based Drug Design of RdRp Inhibitors against SARS-CoV-2. Top. Curr. Chem., 2023, 381(5):22.
[3]Tianji Zhang#, Mingjia Yu#, Honglian Li, Marco Maccarana, Wei Zhang, Deling Shi, Ying Kan, Xiao Zhang, Lianli Chi, Ulf Lindahl, Hongmei Li*, Jin-ping Li*, Tianwei Tan*. Interacting polymer-modification enzymes in heparan sulfate biosynthesis. Carbohydr. Polym., 2023, 299: 120191.
[4]Kiran Shehzadi, Mingjia Yu* and Jianhua Liang*. De Novo Potent Peptide Nucleic Acid Antisense Oligomer Inhibitors Targeting SARS-CoV-2 RNA-Dependent RNA Polymerase via Structure-Guided Drug Design. Int. J. Mol. Sci., 2023, 24(24), 17473.
[5]Binjie Li, Tianji Zhang, Hui Cao, Vito Ferro, Jinping Li*, and Mingjia Yu*. Identification of a Pentasaccharide Lead Compound with High Affinity to the SARS-CoV-2 Spike Protein via In Silico Screening. Int. J. Mol. Sci., 2023, 24, 16115.
[6]Xiaotian Lian, Wentian Liu, Bingzhi Fan, Mingjia Yu*, and Jianhua Liang*. Design, Synthesis and Biological Evaluation of Conjugates of 3-O-Descladinose-azithromycin and Nucleobases against rRNA A2058G- or A2059G-Mutated Strains. Molecules, 2023, 28, 3: 1327.
[7]Mingjia Yu, Huimin Zhao, Yuhui Miao, Shi-Zhong Luo, Song Xue*. Virtual evolution of HVEM segment for checkpoint inhibitor discovery. Int. J. Mol. Sci., 2021, 21;22(12):6638.
[8]Mingjia Yu, Tianji Zhang, Wei Zhang, Qianyun Sun, Hongmei Li*, Jin-ping Li*, Elucidating the Interactions Between Heparin/Heparan Sulfate and SARS-CoV-2-Related Proteins—An Important Strategy for Developing Novel Therapeutics for the COVID-19 Pandemic. Front. Mol. Biosci., 2021, 7:628551.
[9]Binjie Li, Tianji Zhang, Jin-ping Li, Ming-jia Yu*. Identification of Potential Antiviral Disaccharide Leading Compounds against SARS-CoV-2 through A Computer Aided Study. ChemBioChem, 2022, https://doi.org/10.1002/cbic.202200461.
[10]Mingjia Yu*, Tianji Zhang, Jin Ping Li, Yingxia Tan*. Elucidating the Binding Mode between Heparin and Inflammatory Cytokines by Molecular Modeling. Chemistryopen, 2021, 10(10):966-975.
[11]Ying Han, Yifan Da, Mingjia Yu, Yaping Cheng, Xin Wang, Jiale Xiong, Guoying Guo, Yan Li, Xianxing Jiang, Xiaoqing Cai*, Protein labeling approach to improve lysosomal targeting and efficacy of antibody-drug conjugates. Org. Biomol. Chem., 2020, 18(17):3229-3233.
[12]Ming-jia Yu, Shi-Lu Chen*. From Alkane to Alkene: The Inert Aliphatic C−H Bond Activation Presented by Binuclear Iron Stearoyl-CoA Desaturase with a Long di-Fe Distance of 6 Å. ACS Catal., 2019, 9: 4345-4359.
[13]Ming-jia Yu, Shi-Lu Chen*. Mechanism and inhibitor exploration for binuclear Mg ketol-acid reductoisomerase: targeting on the biosynthetic pathway of branched-chain amino acids. ChemBioChem, 2019, 21(3): 381-391.
[14]Wenya Tian, Chenghai Sun, Mei Zheng, Jeffrey Harmer, Mingjia Yu, Yanan Zhang, Haidong Peng, Dongqing Zhu, Zixin Deng, Shi-Lu Chen, Mehdi Mobli, Xinying Jia, and Xudong Qu*, Efficient Biosynthesis of Heterodimeric C3-Aryl Pyrroloindoline Alkaloids. Nat. Commun., 2018, 9: 4428(1-9).
[15]Ming-jia Yu and Shi-Lu Chen*, From NAD+ to Ni Pincer Complex: A Significant Cofactor Evolution Presented by Lactate Racemase. Chem. — Eur. J., 2017, 23(31): 7545-7557.
[16]采用smiles算法随机批量生成肝素类似物结构坐标的方法，于明加;郭霄亮;林煌;李晋萍，授权专利号：ZL202110590305.2
[17]Liu Xingzhou, Yu Mingjia*, Liang Jianhua*. Research Progress on the Synthesis of Protoberberine Skeleton and its Anti-inflammatory Activity[J]. Chinese Journal of Organic Chemistry, 2023, doi: 10.6023/cjoc202209037.